In the phase 3b BE RADIANT randomized clinical trial with a 3-year open-label extension (n=743), bimekizumab, a dual IL-17A/IL-17F inhibitor, produced rapid and sustained improvements in patient-reported symptoms and health-related quality of life in patients with moderate to severe plaque psoriasis, with greater early improvements than secukinumab and durable responses through year 3. High proportions of patients achieved complete skin clearance with minimal quality-of-life impact (Psoriasis Area and Severity Index = 0 and Dermatology Life Quality Index 0/1), and patients who switched from secukinumab to bimekizumab experienced comparable improvements, supporting the therapy’s long-term efficacy and patient-centered benefits.

Source: JAMA Dermatology